Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

1(25%)

Results Posted

67%(2 trials)

Phase Distribution

Ph phase_3

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 3Large-scale testing

4(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Detailed Status

Completed3

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 34 (100.0%)

Trials by Status

recruiting125%

completed375%

Recent Activity

1 active trials

Showing 4 of 4

recruitingphase_3

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb

NCT00432666

Clinical Trials (4)

Showing 4 of 4 trials

NCT05598723Phase 3

BOTOX® vs. XEOMIN® for Chronic Migraine

Recruiting

NCT00406367Phase 3

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

Completed

NCT00541723Phase 3

Efficacy and Safety of NT 201 in the Treatment of Lateral Periorbital Wrinkles

Completed

NCT00432666Phase 3

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4